Headlines like this are becoming common:
FDA approves ‘precision medicine’ drug for different cancers with same mutation
What does it mean? That the most effective cancer treatment isn’t necessarily determined by tumor site – but by biomarkers and mutations found in an array of cancers.
As more cancer drugs are formulated to address the genomic signature of a tumor, oncologists need critical somatic information within their EHR workflow.
But somatic data isn’t enough. Comprehensive genomic information, available to the oncologist within the patient context via 2bPrecise, is transformative.